NCT06176261 - DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2029

Conditions

Breast CancerBreast Cancer FemaleMetastatic Triple-Negative Breast CarcinomaER Positive Breast CancerHER2-negative Breast CancerHER2 Negative Breast CarcinomaER-negative Breast Cancer

Interventions

DRUG

Datopotamab Deruxtecan

Antibody-drug conjugate, 100 mg single-use vial, via intravenous infusion per protocol.

Trial Locations (3)

27710

RECRUITING

Duke University Medical Center, Durham

33176

RECRUITING

Miami Baptist Cancer Institute/, Miami

02215

RECRUITING

Dana-Farber Cancer Institute, Boston